Shield Therapeutics plc (STX.L) LSE
5.85
-0.05(-0.85%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
5.85
-0.05(-0.85%)
Currency In GBp
Address
Northern Design Centre
Gateshead, NE8 3DF
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1915 118 500
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
63
First IPO Date
February 26, 2016
| Name | Title | Pay | Year Born |
| Anders Lundstrom | Chief Executive Officer & Executive Director | 114,447 | 1962 |
| Christian Schweiger | Co-Founder & Non Executive Director | 37,901 | 1966 |
| Lucy Kate Huntington-Bailey | General Counsel, Chief Compliance Officer & Company Secretary | 0 | N/A |
| Andrew Hurley | Chief Commercial Officer | 0 | 1969 |
| Santosh Shanbhag | Chief Financial Officer | 0 | 1978 |
| Carol Akinola | Head of Pharmacovigilance & Medical Information | 0 | N/A |
| Kate Armanetti | Senior Director of People & Culture | 0 | N/A |
| Suzanne Wood | Group HR Director | 0 | N/A |
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.